L’anticorps Poulet Polyclonal anti-APOA1 a été validé pour WB, ELISA et IF. Il convient pour détecter APOA1 dans des échantillons de Humain, Souris et Rat.
N° du produit ABIN6991085
Aperçu rapide pour APOA1 anticorps (N-Term) (ABIN6991085)
ApoA1 Antibody is affinity chromatography purified via peptide column.
Immunogène
ApoA1 antibody was raised against a 17 amino acid synthetic peptide from near the amino terminus of human ApoA1. The immunogen is located within the first 50 amino acids of ApoA1.
APOA1
Reactivité: Humain
WB, IHC
Hôte: Lapin
Polyclonal
unconjugated
Indications d'application
ApoA1 antibody can be used for detection of ApoA1 by Western blot at 1 μ,g/mL. Antibody can also be used for immunoflourescence starting at 20 μ,g/mL. For immunofluorescence start at 20 μ,g/mL.
Antibody validated: Western Blot in human samples and Immunofluorescence in human and mouse samples. All other applications and species not yet tested.
Restrictions
For Research Use only
Format
Liquid
Concentration
1 mg/mL
Buffer
ApoA1 Antibody is supplied in PBS containing 0.02 % sodium azide.
Agent conservateur
Sodium azide
Précaution d'utilisation
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Stock
-20 °C,4 °C
Stockage commentaire
ApoA1 antibody can be stored at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
Antigène
APOA1
(Apolipoprotein A-I (APOA1))
Autre désignation
ApoA1
Sujet
ApoA1 Antibody: Apolipoprotein A1 (ApoA1) is the major protein component of high density lipoprotein (HDL) in plasma. ApoA1 is synthesized in the liver and small intestine and promotes cholesterol efflux from tissues to the liver for excretion. It is a cofactor for lecithin cholesterolacyltransferase (LCAT), the enzyme responsible for the formation of most plasma cholesteryl esters. Defects in ApoA1 are associated with HDL deficiency, Tangier disease, and systemic non-neuropathic amyloidosis.